Otenabant

Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB₁ antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]

Otenabant

Clinical data
ATC code	none
Identifiers
IUPAC name 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)piperidine-4- carboxamide
CAS Number	686344-29-6^Y
PubChem CID	10052040
ChemSpider	8227602^N
UNII	J8211Y53EF
KEGG	D09362^Y
ChEMBL	ChEMBL562668^N
CompTox Dashboard (EPA)	DTXSID20988316
Chemical and physical data
Formula	C25H25Cl2N7O
Molar mass	510.42 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CCNC1(CCN(CC1)C2=NC=NC3=C2N=C(N3C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl)C(=O)N
InChI InChI=1S/C25H25Cl2N7O/c1-2-31-25(24(28)35)11-13-33(14-12-25)22-20-23(30-15-29-22)34(17-9-7-16(26)8-10-17)21(32-20)18-5-3-4-6-19(18)27/h3-10,15,31H,2,11-14H2,1H3,(H2,28,35)^N Key:UNAZAADNBYXMIV-UHFFFAOYSA-N^N
^NY (what is this?)  (verify)

See also

• Cannabinoid receptor antagonist

References

1. Kim MA, Yun H, Kwak H, Kim J, Lee J (2008). "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist". Tetrahedron. 64 (48): 10802–10809. doi:10.1016/j.tet.2008.09.057.
2. Woods SC (November 2007). "The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction". Journal of the American Academy of Physician Assistants. Suppl Endocannabinoid (11): 7–10. doi:10.1097/01720610-200711000-00005. PMID 18047036.
3. "Pfizer Pharmaceutical News and Media - Pfizer: One of the world's premier biopharmaceutical companies". www.pfizer.com.